The Biogen Bump Bodes Well for Biotech


Shares of Biogen took off following upbeat trial data for an Alzheimer's treatment -and it could be a sign that it's safe to start nibbling on the shares of other big biotech stocks as well. Consider: Biogen and its partner Eisai announced positive results from an 18-month study of BAN2401 after the market closed on Thursday.



from Biotech News